Navigation Links
Reminder - Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Systemic Lupus Erythematosus
Date:7/19/2009

ROCKVILLE, Maryland July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will host a conference call today at 8:15 AM Eastern to discuss the results from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 8364417.

This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS, Human Genome Sciences, BENLYSTA and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

[webcast]

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has completed delivery of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to FDA's approval of the Company's Biologics License Application for ABthrax. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reminders Boost Mammography Appointments
2. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
3. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
4. Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients
5. Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
6. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
7. There is No Place Like CareMinders Home Care and the Dedication and Commitment of the Owners
8. Understand Colon Cancer with MyBiopsy.Org; Schedule a Screening Test at MyHealthTestReminder.Org
9. New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use
10. Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Societys Midwinter Meeting
11. Recently Reported Childhood Deaths from Influenza Are a Stark Reminder to Vaccinate Now
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ... ... Reassured For Life ( http://www.reassured.ca ), is now open. , “Reassured For ... Nerissa McNaughton. “I launched this firm because I know talking about life, accident, sickness, ... I make it easy. As a broker I have access to all the life ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine managing ... available on the market," said an inventor from Center Valley, Pa. "My idea is ... patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... 21, 2017 , ... Adolfson & Peterson Construction (AP) along ... County Medical Examiners Facility located in Saint Paul, Minn. A single story, 10,688 ... to start in late 2017/early 2018. , Staffed by 20 full-time employees ...
(Date:7/21/2017)... Connecticut (PRWEB) , ... July 21, 2017 , ... Hospital ... from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the ... of 2017, and up 15% from the 20 announced deals in the year-ago second ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a new ... suffer from painful intercourse and other painful pelvic pain conditions such as ... menopause. ... ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void in ...
(Date:7/10/2017)... 10, 2017  BDI Group subsidiary Pathway Purchasing ... services organization serving specialty pharmacies, home infusion companies ... four significant, value-added member programs designed to help ... reimbursement and improve access and affordability for patients ... Pathway has ...
Breaking Medicine Technology: